BCG vaccine shortage ‘not as grave’


Babies in contact with adults with TB should receive the medicine isoniazid as prophylaxis “which significantly reduces the risk of TB disease”, according to the NAGI, which advises the health department on immunisations.
South Africa been affected by a global shortage of the BCG vaccine caused by manufacturing problems.
In 2012, Sanofi, one of the main manufacturers, developed a problem with one of its stains and had to withdrew its vaccines and this year the other main manufacturer, MSD, also had production problems. However, these will be resolved by the end of 2015.
“South Africa has had shortages of BCG vaccine recently, but the situation has recently improved and will likely normalize soon as alternate supply sources of BCG are being procured by Biovac,” according to NAGI, which is chaired by Professor Gregory Hussey, Director of Vaccines for Africa at the University of Cape Town.
The BCG vaccination protects against “the more severe types of disseminated TB, such as miliary (disseminated) TB and tuberculosis meningitis” but offers only partial protection against pulmonary (lung) TB, the commonest form of TB affecting children and adults in South Africa.
“A newborn that had not received the BCG dose soon after birth can be given a dose until 12 months of age. This is in line with the official WHO recommendations. Delayed administration of BCG by a matter of weeks is unlikely to be detrimental, with some evidence suggesting that delaying BCG vaccination might even improve the immune response to the vaccine, since the immune system matures with age,” according to NAGI.
“There is thus no reason for social isolation of newborns who have not received the BCG vaccine. Any child, irrespective of whether immunised with BCG, should be taken to the nearest clinic if there is any suspicion of having been exposed to an adult with TB, or if there are potential symptoms of TB, such as loss of weight or persistent coughing.”
An edited version of this story was also published on Health24.com
Author
Republish this article

This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
-
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
-
You must include all of the links from our story, including our newsletter sign up link.
-
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
-
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
-
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
-
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
-
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
BCG vaccine shortage ‘not as grave’
by kerrycullinan, Health-e News
November 12, 2015